Pipeline
As infectious diseases keep spreading across the globe, threatening the human race.
expanding the vaccine market is critical more than ever.
expanding the vaccine market is critical more than ever.
SK bioscience will continue to invest in vaccine R&D which will be the driving force of life science business
to secure the newest technology and expand a product portfolio.
Domestic Vaccine Market
Immunization through vaccination has become the most important public health policy in the world to prevent the outbreak of transboundary epidemics.
(Year of 2022~2028, Unit: million $)
- 0
- 20
- 40
- 60
- 80
- 100
- 120
2022
2023
2024
2025
2026
2027
2028
Source : Evaluate Pharma (2024.02)
The premium vaccine market is growing as the aging population is rapidly increasing.
The growing vaccine industry is resulting in better profitability, introduction of new R&D and manufacturing technologies, and new funding opportunities.
In recent years, the development of therapeutic vaccines which can treat currently existing diseases is also on the rise.
Vaccines are the most effective, efficient, and convenient to prevent and treat infectious diseases.Immunization through vaccination has become the most important public health policy in the world to prevent the outbreak of transboundary epidemics.
Vaccine Pipeline
Premium
Basic Vaccine
COVID-19/Pandemic Response
| Basic Research / Preclinical | Phase I Clinical Trial | Phase II Clinical Trial | Phase III Clinical Trial | Commercialization | |
|---|---|---|---|---|---|
21-Valent Pneumococcal Conjugate Vaccine  |
 Global |
||||
RSV Vaccine |
|
||||
Herpes Zoster Vaccine |
|
||||
10-Valent HPV Vaccine  |
|
||||
Cell Culture-based Inlfuenza Vaccine |
|
||||
13-Valent Pneumococcal Vaccine |
|
||||
SKYCellflu(Cell Culture-based Trivalent Influenza) |
Applied WHO PQ |
||||
SKYCellflu(Cell Culture-based Quadrivalent Influenza) |
Applied WHO PQ |
||||
SKYZoster(Herpes Zoster Vaccine) |
|
||||
SKYVaricella(Varicella Vaccine) |
Applied WHO PQ |
||||
SKYTyphoid(Typhoid Conjugate Vaccine)   |
Applied WHO PQ |
||||
4-valent HPV vaccine |
Phase I/II Clinical Trial |
||||
Rotavirus Vaccine |
|
||||
Japanese encephalitis vaccinemRNA  |
|
||||
Hepatitis A, etc |
|
||||
SKYCovione(COVID-19 Vaccine) |
Achieved BLA / of SKYCovione (KMFDS) |
||||
Universal Coronavirus Vaccine (Sarbecovirus)  |
|
||||
Lassa fever VaccinemRNA |
|
||||
Nasal Spray  |
|